Clinical Trials Directory

Trials / Completed

CompletedNCT02248155

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Sifrol® Onset of Action and Impact on RLS: A 12-week Observational Study in Patients With Primary RLS

Status
Completed
Phase
Study type
Observational
Enrollment
2,644 (actual)
Sponsor
Boehringer Ingelheim · Industry
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The objectives of this Post Marketing Surveillance (PMS) are: * Evaluation of the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Syndrome Scale (IRLS) and Clinical Global Impression Improvement scale (CGI- I) * Evaluation of the time to reaching maintenance dose of pramipexole * Evaluation of work productivity impairment associated with RLS based on the Work Productivity and Activity Impairment Questionnaire (WPAI) questionnaire

Conditions

Interventions

TypeNameDescription
DRUGPramipexole

Timeline

Start date
2006-04-01
Primary completion
2006-11-01
First posted
2014-09-25
Last updated
2014-09-25

Source: ClinicalTrials.gov record NCT02248155. Inclusion in this directory is not an endorsement.

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS) (NCT02248155) · Clinical Trials Directory